Biotech pharma

Invitris

Website

Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic

Founded 2022Origin source ↗Checked 2026-09-15

Overview

Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material.

Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.

Company description As recorded 2026-11-08
LinkedIn
Biotech pharmaBusinessesEnterpriseLicensing

Founders & team

Patrick Grossmann

Founder

My hearts are entrepreneurship & science, originally trained as bioinformatician at the Harvard Medical School and ETH Zurich amongst other schools. I earned a PhD and MBA, and highly enjoy opportunities to improve the world with science-based products. I co-founded Invitris to radically simplify drug development to stop antibiotic-resistance, which has the potential to become the dominating health-economic challenge in this century.

LinkedIn
Founder profile As recorded 2026-09-15

Kilian Vogele

Founder

Kilian, the CTO and co-founder of Invitris, is responsible for driving innovation and development within the company. With a PhD in synthetic biology from TUM and a track record of 5 patents, his expertise has been instrumental in creating Invitris' groundbreaking technology.

LinkedIn
Founder profile As recorded 2026-09-15
6team members reported
Source-reported As recorded 2026-09-15

Founded 2022 · Source

News & product activity

Sources & observations

Y Combinator

Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedMunich, BY, Germany
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented

Source-based assessment · automated evidence rules

The retained text does not establish product availability or customer use.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplesourced founding year
startup.observe Directory coverage · Sources & method